Who We Are

Biosimilars Canada is the voice of Canada’s biosimilar medicines industry. It provides leadership in educating Canadian stakeholders about biosimilar medicines, and advocating for federal and provincial policies that support the approval, reimbursement and market acceptance of biosimilars.

International alignment of regulatory requirements is needed to support investment, research, development and approval of biosimilar medicines. Canadian-specific requirements add unnecessary delays and costs, and will limit the availability of biosimilars to Canadians.

In collaboration with its partners in the International Generic and Biosimilar Medicines Association (IGBA), Biosimilars Canada seeks to address global developments for the biosimilar medicines industry at the World Health Organization (WHO), and with the International Conference on Harmonization (ICH) and other standards-setting bodies.

 

Biosimilars Canada Board

Michel Robidoux (Chair) ...... Sandoz

Mike Woolcock ...... Apobiologix

Matthew Rotenberg ...... Fresenius Kabi

David Simpson ...... Mylan

Jean-Guy Goulet ...... Pharmascience

Barb Pimental ......Taro

Doug Sommerville......Teva

Jim Keon (Ex-Officio) ...... Biosimilars Canada

 

Member Companies

 

Acic Apobiologix Fresenius Kabi Mylan Pharma science Sandoz Taro Teva